B 细胞成熟抗原 CAR-T 细胞治疗缓解多发性骨髓瘤患者的心力衰竭

Patients with multiple myeloma (MM) are likely to achieve poor therapeutic response when organs are involved.

We produced anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR)-T cells, which are in a trial for patients with relapsed/refractory MM. One enrolled patient developed severe heart failure, highly suspected as light chain cardiac amyloidosis. He exhibited increased N-terminal pro-brain natriuretic peptide with a peak of 32 299 ng/mL and heart failure with an ejection fraction of 30%.

Anti-BCMA CAR-T cells were administered following lymphodepletion. The patient achieved cardiac response within 1 week with a decrease in N-terminal pro-brain natriuretic peptide by 80%, an increase in ejection fraction from 30% to 56%, and a haematological response with negative minimal residual disease at 1 month and a complete response at 1 year. To date, this patient has maintained good health without heart failure or haematological relapse.

Herein, we show the efficacy of anti-BCMA CAR-T cells in patients with MM and severe heart failure.